Strategies in the design of nanoparticles for therapeutic applications

By Robby A. Petros, Joseph M. DeSimone. Nature reviews. Drug discovery, 2010

3,477 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Functionalized Gold Nanoparticles and Their Biomedical Applications (2011, background): “Gold nanoparticles (GNPs) and their biomedical applications have been reviewed recently indicating enormous growth in this field [5–8].”
Nanoparticle PEGylation for imaging and therapy (2011, background): “In the mid-1990s, Doxil® (liposomal delivery vehicle for doxorubicin) and oncospar (PEG-Lasparaginase) became the first FDA-approved NP therapeutics [40].”
Enzyme-responsive nanoparticles for drug release and diagnostics. (2012, background): “Polymeric nanomaterials that combine biorecognition sites with controlled drug release capability are being designed to target and kill diseased tissue in a specific way, therefore reducing the unwanted side effects of the drug in the body [9–11].”
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. (2014, background): “Besides the effect on circulation properties and tumor accumulation aforementioned [82, 109], the shape of NP seems to influences the cell uptake kinetics and internalization pathways by modulating the interactions between the nanomaterial and the cell surface [211, 213].”
Molecularly Self-Assembled Nucleic Acid Nanoparticles for Targeted In Vivo siRNA Delivery (2012, background): “It has been suggested that the optimal particle size for a cancer targeting nanodelivery carrier is 20–100 nm 3,4,17 .”